Latest Share Options News

Xingye Gold (Hong Kong) Mining Company Limited has opened an off-market takeover bid for Far East Gold Limited at $0.13 per share, offering a significant premium amid stalled projects and funding concerns.

Bio-Gene Technology has expanded its capital raise to $2.775 million through a share placement priced at 2.5 cents, attaching options exercisable at 3.5 cents pending shareholder approval.

Metro Performance Glass has significantly improved its financial footing in FY26, cutting net debt by more than half and boosting EBITDA before significant items to $18.2 million despite subdued markets in New Zealand and Australia.

Anax Metals has closed the second tranche of its placement, raising $4.8 million through a share issue that included $1.1 million from directors and granted options to its lead manager.

Thrive Tribe Technologies (ASX:1TT) is issuing approximately 116.87 million Loyalty Options to shareholders at no cost, exercisable at $0.003 each and expiring in 2029, aiming to reward loyalty and potentially raise capital upon exercise.

Australian Strategic Materials Limited (ASM) shareholders are set to vote on a scheme of arrangement for Energy Fuels Inc. to acquire 100% of ASM shares and options, offering a significant premium and exposure to a vertically integrated rare earth supply chain.

Helix Resources (ASX:HLX) is set to consolidate its securities on a 1-for-35 basis, dramatically reducing the number of shares, options, and performance rights on issue. The move aims to streamline the capital structure ahead of upcoming exploration milestones.

Caspin Resources has agreed to sell its entire Mount Squires Project interest to Agrimin Limited, receiving shares, options, performance rights, and a royalty, while concentrating on advancing its high-grade Bygoo Tin Project in New South Wales.

Agrimin Limited has secured a large exploration package in Western Australia's West Musgrave region, acquiring the Mount Squires Project from Caspin Resources. The project offers promising gold and base metal targets along strike from BHP’s Nebo and Babel deposits.

Nagambie Resources has completed all conditions precedent following strong shareholder approval for an earn-in joint venture with Alkane Resources, enabling Alkane to acquire up to an 80% interest through staged funding over five years.

Chimeric Therapeutics Limited has announced a significant 100-to-1 security consolidation affecting shares, options, and performance rights, pending shareholder approval and set for implementation in April 2026.

EOS management, including CEO Dr Andreas Schwer and CFO Clive Cuthell, have exercised over 3.3 million share options, with the CEO set to sell a significant portion to fund personal commitments.